Children's Mercy operates the largest pediatric clinical pharmacology program in North America. Building on our internationally
recognized strength in clinical pharmacology and national reputation and stature within the Children's Oncology Group, Children’s
Mercy is developing an integrated Phase I Experimental Therapeutics Program.
As a joint collaboration between Hematology/Oncology and Clinical Pharmacology at Children's Mercy, the Experimental Therapeutics
in Pediatric Cancer Program is being led by Kathleen Neville, MD, MS,
Divisions of Pediatric Clinical Pharmacology and Medical Toxicology, and Keith August, MD, MS, Hematology/Oncology. Dr. Neville is board certified in both disciplines. She has had extensive training in experimental
therapeutics for children with cancer and has also done a considerable amount of research in the area of pediatric sickle-cell disease.
In addition to her work with hydroxyurea, she has also studied other medications used to treat pain in patients with sickle-cell disease.
Development of more effective chemotherapy treatment for pediatric cancers requires understanding of both the pharmacology of anti-cancer
agents and the means by which tumors develop drug resistance. Children's Mercy is well-positioned for this research, with a high volume of
cancer patients and an extensive track record in pharmacology clinical trials research that includes leadership in pediatric labeling for 35
separate medications since the Best Pharmaceuticals for Children Act of 2002.
"We are committed to providing world-class interdisciplinary care for patients with refractory/recurrent pediatric cancers who require
experimental therapy," says Dr. Neville. "We owe it to our children now and the children of the future to do this research."